Join us as Lincoln Nadauld, CEO of Culmination Bio, delves into the crucial role of genomics-powered precision medicine in Oncology research. Discover the main challenges hindering the adoption of precision medicine in clinical oncology. Gain insights on effectively managing your time between clinical medicine and the industry. Don't miss Lincoln's inspiring journey!

Lincoln Nadauld is the CEO of Culmination Bio, a biotech company leveraging unique data sets from diverse biosamples containing vast biological data enriched with clinical data.

He was VP and Chief of Precision Health and Academics at Intermountain Healthcare, where he led precision health across 24 hospitals and 200 clinics, overseeing Graduate Medical Education. He is the co-founder of Clarified Precision Medicine as well as Guidance Genome.

Lincoln graduated from Bountiful High School. He played rugby while getting his undergraduate degree at BYU, his Doctor of Medicine, and his Doctor of Philosophy from the University of Utah. Then he did his clinical training in oncology at Stanford University.

We volunteer our time and money to make this content freely available – if you enjoy our content and find it helpful, you can support us by buying us a coffee here!